Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Account Payables (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Change in Account Payables for 7 consecutive years, with $17.5 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 567.96% to $17.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.6 million through Dec 2025, up 1659.85% year-over-year, with the annual reading at $26.6 million for FY2025, 1659.85% up from the prior year.
  • Change in Account Payables hit $17.5 million in Q4 2025 for BridgeBio Pharma, up from -$7.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $17.6 million in Q1 2025 to a low of -$11.7 million in Q3 2021.
  • Historically, Change in Account Payables has averaged $1.7 million across 5 years, with a median of $198000.0 in 2023.
  • Biggest YoY gain for Change in Account Payables was 5061.41% in 2024; the steepest drop was 618.88% in 2024.
  • Year by year, Change in Account Payables stood at $1.5 million in 2021, then fell by 6.59% to $1.4 million in 2022, then surged by 349.42% to $6.2 million in 2023, then crashed by 160.56% to -$3.7 million in 2024, then surged by 567.96% to $17.5 million in 2025.
  • Business Quant data shows Change in Account Payables for BBIO at $17.5 million in Q4 2025, -$7.4 million in Q3 2025, and -$1.1 million in Q2 2025.